Navigation Links
Shengtai Pharmaceutical, Inc. to Present at Roth Conference
Date:2/7/2008

WEIFANG, China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced its CFO, Mr. Yizhao Zhang, will present at the upcoming Roth 20th Annual OC Growth Stock Conference in Dana Point, California.

The date, time and location of Shengtai Pharmaceutical, Inc.'s presentation at the conference are as follows:

Date: Thursday, February 21, 2008

Time: 10:30 a.m. Pacific Time

Venue: Ritz Ballroom Salon 1

The Ritz Carlton Laguna Niguel

One Ritz-Carlton Drive

Dana Point, California 92629

Webcast: http://www.wsw.com/webcast/roth16/sgti/

A replay of the call will be available for 90 days following the presentation using the same link and will also be available on the Company's website.

The ROTH 20th Annual OC Conference will feature presentations from over 300 small-cap companies including over 40 U.S.-listed Chinese companies. The distinguished list of presenting companies have been identified by Roth Capital's award-winning research team and are representative of a broad spectrum of sectors, including Technology, Healthcare, Energy and Industrial as well as Consumer Products.

Interested parties and investors may find more information for the conference by visiting the website at http://www.rothcapital.com.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the holding company for Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc. please visit http://www.shengtaipharmaceutical.com.

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
4. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
7. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, Inc. ... genome editing, announced that the U.S. Food and ... New Drug (IND) application for SB-318, a single ... for Mucopolysaccharidosis Type I (MPS I). The SB-318 ... to initiate a Phase 1/2 clinical study (SB-318-1502) ...
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, PLC, ... eine Infografik mit dem Titel „Epilepsy Around ... mit der der Krankheit gegenüber ein größeres ... ermutigen soll, Medikamentenresistenz bei Epilepsie auf dem ... Diskussion zu machen. Mithilfe der neuen Infografik ...
Breaking Medicine Technology: